Genomic Health launched its prostate cancer diagnostic this week with great fanfare, backed by seven studies including over 1,100 patients. The challenge ahead: convincing men that results telling them they can wait for more drastic and expensive treatment options are to be believed.
Myriad Genetics and Genomic Health lead the bill of companies introducing new prostate cancer diagnostics that promise to change the standard of care, but as the market crowds, payers may balk at the cost while physicians struggle to decide which test is best.
Genomic Health and OncoMed Pharmaceuticals have an agreement to identify new biomarkers useful for future companion diagnostics that would go along with OncoMed's cancer drugs now in development.
With use of molecular diagnostics tests widely expected to skyrocket in the coming decade, UnitedHealth Group is getting increasingly nervous about the trend and looking for ways to manage their use and expense.
Next-generation sequencing (NGS)--faster and cheaper genome sequencing--has revolutionized the search for genes connected with disease, and each week more DNA- and RNA-based biomarkers are found. In